CA1258426A - Synergistic mixtures of interferons and tumor necrosis-factor - Google Patents
Synergistic mixtures of interferons and tumor necrosis-factorInfo
- Publication number
- CA1258426A CA1258426A CA000484739A CA484739A CA1258426A CA 1258426 A CA1258426 A CA 1258426A CA 000484739 A CA000484739 A CA 000484739A CA 484739 A CA484739 A CA 484739A CA 1258426 A CA1258426 A CA 1258426A
- Authority
- CA
- Canada
- Prior art keywords
- interferon
- type
- necrosis factor
- tumour necrosis
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 102000014150 Interferons Human genes 0.000 title claims abstract description 48
- 108010050904 Interferons Proteins 0.000 title claims abstract description 48
- 229940047124 interferons Drugs 0.000 title claims description 24
- 230000002195 synergetic effect Effects 0.000 title claims description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title 1
- 102000003390 tumor necrosis factor Human genes 0.000 title 1
- 102000018594 Tumour necrosis factor Human genes 0.000 claims abstract description 65
- 108050007852 Tumour necrosis factor Proteins 0.000 claims abstract description 65
- 229940079322 interferon Drugs 0.000 claims abstract description 26
- 239000000824 cytostatic agent Substances 0.000 claims abstract description 14
- 230000001085 cytostatic effect Effects 0.000 claims abstract description 14
- 241000282414 Homo sapiens Species 0.000 claims description 53
- 108010074328 Interferon-gamma Proteins 0.000 claims description 39
- 102000008070 Interferon-gamma Human genes 0.000 claims description 32
- 102000002227 Interferon Type I Human genes 0.000 claims description 30
- 108010014726 Interferon Type I Proteins 0.000 claims description 27
- 239000012535 impurity Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000010353 genetic engineering Methods 0.000 claims 11
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 29
- 230000001472 cytotoxic effect Effects 0.000 abstract description 6
- 231100000433 cytotoxic Toxicity 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 12
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 108010047761 Interferon-alpha Proteins 0.000 description 7
- 102000006992 Interferon-alpha Human genes 0.000 description 7
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 7
- 239000002609 medium Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000005289 controlled pore glass Substances 0.000 description 2
- 102000057041 human TNF Human genes 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000017066 negative regulation of growth Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 101000999325 Homo sapiens Cobalamin binding intrinsic factor Proteins 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101001054328 Mus musculus Interferon beta Proteins 0.000 description 1
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- DLEDLHFNQDHEOJ-UDTOXTEMSA-N mezerein Chemical compound O([C@@H]1[C@H]([C@@]23[C@H]4[C@](C(C(C)=C4)=O)(O)[C@H](O)[C@@]4(CO)O[C@H]4[C@H]3[C@H]3O[C@@](O2)(O[C@]31C(C)=C)C=1C=CC=CC=1)C)C(=O)\C=C\C=C\C1=CC=CC=C1 DLEDLHFNQDHEOJ-UDTOXTEMSA-N 0.000 description 1
- DLEDLHFNQDHEOJ-KVZAMRGJSA-N mezerein Natural products CC1C(OC(=O)C=C/C=C/c2ccccc2)C3(OC4(OC3C5C6OC6(CO)C(O)C7(O)C(C=C(C)C7=O)C15O4)c8ccccc8)C(=C)C DLEDLHFNQDHEOJ-KVZAMRGJSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 108700029353 mouse Ifna Proteins 0.000 description 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19843423234 DE3423234A1 (de) | 1984-06-23 | 1984-06-23 | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
| DEP3423234.6 | 1984-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1258426A true CA1258426A (en) | 1989-08-15 |
Family
ID=6238998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000484739A Expired CA1258426A (en) | 1984-06-23 | 1985-06-21 | Synergistic mixtures of interferons and tumor necrosis-factor |
Country Status (16)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879226A (en) * | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
| DE3423234A1 (de) * | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
| AU601675B2 (en) * | 1984-12-21 | 1990-09-20 | Biogen, Inc. | Purification, production and use of tumor necrosis factors |
| NZ219027A (en) * | 1986-01-24 | 1989-09-27 | Genentech Inc | Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin |
| US4828830A (en) * | 1986-01-24 | 1989-05-09 | Genentech, Inc. | Method and composition for prophylaxis and treatment of viral infections |
| US4822605A (en) * | 1986-02-18 | 1989-04-18 | Exovir, Inc. | Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like |
| CA1291706C (en) * | 1986-04-03 | 1991-11-05 | Alfred Rudolph | COMBINATION THERAPY USING INTERFERON-.beta. AND INTERLEUKIN-2 |
| US4863727A (en) * | 1986-04-09 | 1989-09-05 | Cetus Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
| US5425940A (en) * | 1986-04-09 | 1995-06-20 | Cetus Oncology Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
| CA1290249C (en) * | 1986-04-09 | 1991-10-08 | Cetus Corporation | COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR |
| PT85076B (pt) * | 1986-06-16 | 1990-07-31 | Genentech Inc | Metodo para o tratamento de doencas infecciosas pela administracao de factor de necrose tumoral-alfa |
| US5362490A (en) * | 1986-07-25 | 1994-11-08 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Human myelomonocyte interferon-gamma, and process for preparation and use thereof |
| IL80005A (en) * | 1986-09-10 | 1992-11-15 | Yeda Res & Dev | Compositions for modulating the effect of tnf and il-1 |
| US4929442A (en) * | 1986-09-26 | 1990-05-29 | Exovir, Inc. | Compositions suitable for human topical application including a growth factor and/or related materials |
| US4980160A (en) * | 1986-10-16 | 1990-12-25 | Biogen, Inc. | Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases |
| US4963354A (en) * | 1987-01-21 | 1990-10-16 | Genentech, Inc. | Use of tumor necrosis factor (TNF) as an adjuvant |
| EP0392300B1 (de) * | 1989-04-11 | 1992-08-26 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Verwendung von mindestens ein Cytokin zur Herstellung eines Arzneimittels zur systemischen Behandlung von präneoplastischen Läsionen |
| US6042837A (en) * | 1989-09-20 | 2000-03-28 | Kalland; Terje | Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC) |
| US6126945A (en) * | 1989-10-03 | 2000-10-03 | Pharmacia Ab | Tumor killing effects of enterotoxins, superantigens, and related compounds |
| US5676942A (en) * | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
| RU2129437C1 (ru) * | 1992-02-10 | 1999-04-27 | Интерферон Сайнс Инк. | Композиция альфа-интерферона и способ ее получения из лейкоцитов крови человека |
| CA2200879A1 (en) * | 1995-07-25 | 1997-02-13 | Nobutaka Ida | Drug for treating bone disorders |
| US6617171B2 (en) * | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
| US6599710B1 (en) | 1999-03-10 | 2003-07-29 | The General Hospital Corporation | Treatment of autoimmune disease |
| PT1238070E (pt) * | 1999-12-13 | 2007-11-06 | Bioniche Life Sciences Inc | Oligonucleótidos sintéticos úteis sob o ponto de vista terapêutico |
| US20020091095A1 (en) * | 1999-12-13 | 2002-07-11 | Phillips Nigel C. | Modulation of Fas and FasL expression |
| IT1317835B1 (it) * | 2000-02-15 | 2003-07-15 | San Raffaele Centro Fond | Citochine modificate per uso nella terapia del cancro. |
| US7109303B2 (en) * | 2000-02-15 | 2006-09-19 | Fondazione Centro San Raffaele Del Monte Tabor | Modified cytokines for use in cancer therapy |
| US7309694B2 (en) * | 2000-02-15 | 2007-12-18 | Fondazione Centro San Raffaele Del Monte Tabor | Modified cytokines for use in cancer therapy |
| US20020150541A1 (en) * | 2000-09-12 | 2002-10-17 | Gene Trol Biotherapeutics, Inc. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| US20030129162A1 (en) * | 2000-09-12 | 2003-07-10 | Lau Allan S. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| JP2004529851A (ja) * | 2000-09-12 | 2004-09-30 | ジーントロール バイオセラピューティクス， インコーポレイテッド | ヒトサイトカインの混合物を含む組成物およびその産生方法 |
| ES2289303T3 (es) * | 2002-02-06 | 2008-02-01 | Ares Trading S.A. | Factor de necrosis tumoral combinado con interferon en enfermedades desmielinantes. |
| GB0209893D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| GB0209896D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| US7628988B2 (en) | 2002-06-27 | 2009-12-08 | The General Hospital Corporation | Methods and compositions for treating type 1 diabetes |
| US7582313B2 (en) | 2002-06-27 | 2009-09-01 | The General Hospital Corporation | Methods of organ regeneration using Hox 11-expressing pluripotent cells |
| US20040229785A1 (en) * | 2002-11-15 | 2004-11-18 | Denise Faustman | Screening methods to identify treatments for autoimmune disease |
| MXPA05005921A (es) | 2002-12-02 | 2005-10-19 | Abgenix Inc | Anticuerpos dirigidos a factor de necrosis tumoral y sus usos. |
| EP1691852A2 (en) * | 2003-11-10 | 2006-08-23 | Angiotech International AG | Medical implants and fibrosis-inducing agents |
| US20080102054A1 (en) * | 2005-01-18 | 2008-05-01 | Faustman Denise L | Compositions Containing Agm Cells And Methods Of Use Thereof |
| DE102012024749A1 (de) | 2012-12-11 | 2014-06-26 | Martin Röcken | Tumorprävention und -therapie durch Induktion einer Tumorseneszenz |
| HRP20211353T1 (hr) | 2013-02-07 | 2021-11-26 | The General Hospital Corporation | Postupci za ekspanziju ili depleciju regulacijskih t-stanica |
| WO2015057968A2 (en) | 2013-10-17 | 2015-04-23 | The General Hospital Corporation | Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same |
| FI3447075T3 (fi) | 2015-05-15 | 2023-11-07 | Massachusetts Gen Hospital | Antagonistisia anti-tuumorinekroositekijäreseptorin superperheen vasta-aineita |
| EP3340999A4 (en) | 2015-08-28 | 2019-06-12 | The General Hospital Corporation | AGONISTIC ANTI-TUMOR NECROSIS RECEPTOR 2 ANTIBODIES |
| WO2017059132A1 (en) | 2015-09-29 | 2017-04-06 | The General Hospital Corporation | Methods of treating and diagnosing disease using biomarkers for bcg therapy |
| CA3023930A1 (en) | 2016-05-13 | 2017-11-16 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
| WO2019147837A2 (en) * | 2018-01-24 | 2019-08-01 | Beijing Percans Oncology Co. Ltd. | Cytokine fusion proteins |
| CN114436088A (zh) * | 2020-11-02 | 2022-05-06 | 奥的斯电梯公司 | 用于电梯轿厢的安全出口组件及电梯系统 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2513124B1 (fr) * | 1981-07-21 | 1989-11-17 | Hayashibara Biochem Lab | Production et applications du facteur de lyse des cellules-cibles |
| JPH0764744B2 (ja) * | 1981-11-21 | 1995-07-12 | 株式会社林原生物化学研究所 | 標的細胞障害性因子とヒトインタ−フェロンとを有効成分として含有する悪性腫瘍治療剤 |
| IL71954A0 (en) * | 1983-06-01 | 1984-09-30 | Genentech Inc | Gamma interferon-lymphotoxin synergism |
| CA1265444A (en) * | 1983-06-27 | 1990-02-06 | Lloyd J. Old | Effect of human tumor necrosis factor and human interferon on human cancer cells and methods |
| DE3421731A1 (de) * | 1984-06-12 | 1985-12-12 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Humaner-tumor-nekrose-faktor |
| DE3423234A1 (de) * | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
-
1984
- 1984-06-23 DE DE19843423234 patent/DE3423234A1/de not_active Ceased
-
1985
- 1985-06-19 GR GR851492A patent/GR851492B/el unknown
- 1985-06-20 AT AT85107618T patent/ATE82508T1/de not_active IP Right Cessation
- 1985-06-20 EP EP85107618A patent/EP0170843B1/de not_active Expired - Lifetime
- 1985-06-20 PH PH32429A patent/PH24406A/en unknown
- 1985-06-20 DE DE8585107618T patent/DE3586833D1/de not_active Expired - Fee Related
- 1985-06-20 US US06/746,793 patent/US4791101A/en not_active Expired - Fee Related
- 1985-06-21 JP JP60135823A patent/JPS6115842A/ja active Pending
- 1985-06-21 HU HU852456A patent/HU206270B/hu unknown
- 1985-06-21 IL IL75597A patent/IL75597A/xx not_active IP Right Cessation
- 1985-06-21 DK DK282585A patent/DK282585A/da not_active Application Discontinuation
- 1985-06-21 DD DD85277633A patent/DD238725A5/de not_active IP Right Cessation
- 1985-06-21 NZ NZ212513A patent/NZ212513A/xx unknown
- 1985-06-21 CA CA000484739A patent/CA1258426A/en not_active Expired
- 1985-06-21 DD DD85295292A patent/DD250053A5/de not_active IP Right Cessation
- 1985-06-21 ZA ZA854682A patent/ZA854682B/xx unknown
- 1985-06-21 AU AU43931/85A patent/AU593212B2/en not_active Ceased
- 1985-06-21 IE IE154785A patent/IE59289B1/en not_active IP Right Cessation
- 1985-06-24 AU AU44167/85A patent/AU4416785A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| HUT37891A (en) | 1986-03-28 |
| HU206270B (en) | 1992-10-28 |
| AU4393185A (en) | 1986-01-02 |
| AU593212B2 (en) | 1990-02-08 |
| DK282585A (da) | 1985-12-24 |
| NZ212513A (en) | 1988-08-30 |
| DE3586833D1 (de) | 1992-12-24 |
| ATE82508T1 (de) | 1992-12-15 |
| PH24406A (en) | 1990-06-13 |
| US4791101A (en) | 1988-12-13 |
| DD238725A5 (de) | 1986-09-03 |
| AU4416785A (en) | 1986-01-02 |
| IE59289B1 (en) | 1994-02-09 |
| EP0170843B1 (de) | 1992-11-19 |
| DE3423234A1 (de) | 1986-02-06 |
| IL75597A0 (en) | 1985-10-31 |
| DD250053A5 (de) | 1987-09-30 |
| EP0170843A1 (de) | 1986-02-12 |
| IE851547L (en) | 1985-12-23 |
| IL75597A (en) | 1991-11-21 |
| GR851492B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1985-11-25 |
| ZA854682B (en) | 1987-02-25 |
| JPS6115842A (ja) | 1986-01-23 |
| DK282585D0 (da) | 1985-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1258426A (en) | Synergistic mixtures of interferons and tumor necrosis-factor | |
| Le et al. | Biology of disease | |
| Bellone et al. | Regulation of NK cell functions by TGF-β 1 | |
| Tsujimoto et al. | Interferon-gamma enhances expression of cellular receptors for tumor necrosis factor. | |
| Brunda et al. | Inhibition of experimentally‐induced murine metastases by recombinant alpha interferon: correlation between the modulatory effect of interferon treatment on natural killer cell activity and inhibition of metastases | |
| IE64765B1 (en) | Use of cytokines | |
| Schiller et al. | Synergistic antitumor effects of tumor necrosis factor and γ-interferon on human colon carcinoma cell lines | |
| EP0107498A2 (en) | Synergistic human interferon activity | |
| Ortaldo et al. | Analysis of cytostatic/cytotoxic lymphokines: relationship of natural killer cytotoxic factor to recombinant lymphotoxin, recombinant tumor necrosis factor, and leukoregulin. | |
| Fiers et al. | Lymphokines and monokines in anti-cancer therapy | |
| RU2114633C1 (ru) | Композиция для воздействия на опухолевые клетки | |
| Adolf | Structure and effects of interferon-gamma | |
| FLEISCHMANN JR et al. | Requirement for IFN gamma in potentiation of interferon's antiviral and anticellular activities: identity of mouse and human systems | |
| Pfizenmaier et al. | Tumor necrosis factor (TNF) alpha: control of TNF-sensitivity and molecular mechanisms of TNF-mediated growth inhibition | |
| Borden et al. | Preclinical and clinical studies of interferons and interferon inducers in breast cancer | |
| HUGHES et al. | Do the interferons act singly or in combination? | |
| AU660493B2 (en) | Method for treatment of chronic lymphocytic leukemia using interleukin -6 | |
| Oritani et al. | Interferon-ζ/limitin: novel type I interferon that displays a narrow range of biological activity | |
| Ruggiero et al. | The in vitro antiviral activity of tumor necrosis factor (TNF) in WISH cells is mediated by IFN-β induction | |
| Rathjen et al. | Differential effects of small tumour necrosis factor-alpha peptides on tumour cell cytotoxicity, neutrophil activation and endothelial cell procoagulant activity | |
| Fleischmann Jr et al. | Potentiating effect of murine interferon-γ-containing lymphokine preparations on the antiviral and antiproliferative effects of murine interferon-α/β: identification of the potentiation factor as murine interferon-γ itself | |
| HONG et al. | Colony Inhibitory Effect of Recombinant Human Tumor Necrosis Factor (rH-TNF) and/or Recombinant Human Interferon (rH-IFN)-α-β and-γ on Human Lung Cancer Cell Lines | |
| Jacobsen et al. | Interferons: I. Their origin and actions | |
| Lin et al. | Inhibition of tumour necrosis factor and natural cytotoxic cell lytic activities by a spleen cell-elaborated factor | |
| Chapekar et al. | Potentiation of the cytocidal effect of human immune interferon by different synthetic double-stranded RNAs in the refractory human colon carcinoma cell line BE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |